Upon correlating our study's findings with the existing literature, we observed that silencing FGF8 in ovarian cancer cells resulted in the downregulation of several proteins associated with cancer progression, including SLC7A5, FHL2, SPATS2L, and DAD1. The gene discussed is FHL2; the disease is ovarian carcinoma.